Summary
This prediction is currently active. With a performance of -3.54%, the BUY prediction for Bayer AG by ROKOBA is down slightly. This prediction currently runs until 19.02.26. The prediction end date can be changed by ROKOBA at any time. ROKOBA has 90% into this predictionBayer is a multinational pharmaceutical and life sciences company headquartered in Germany. The company was founded in 1863 and has since grown to become a global leader in the fields of pharmaceuticals, agriculture, and consumer health. Bayer is listed on the Frankfurt Stock Exchange and also trades over-the-counter in the United States under the ticker symbol BAYZF. The company's products include prescription drugs, over-the-counter medicines, and agrochemicals, and it operates in more than 90 countries around the world.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Bayer AG | -3.54% |
| iShares Core DAX® | -1.875% |
| iShares Nasdaq 100 | -2.177% |
| iShares Nikkei 225® | -0.867% |
| iShares S&P 500 | -1.253% |
According to ROKOBA what are the pros and cons of Bayer AG for the foreseeable future?
Pros
Higher EBIT margin than peer group
Could be worthwhile Investment >10% per year
EBIT growth >5% per year expected
Fair valuation
positive Cash Flow expected
High dividend yield expected
Revenue growth >5% per year expected
Good rating
Valuable balance sheet
Standard Investments for future growth
ROE higher than 10% per year
Normal challenges to pay loans and raise capital
Capable Management
Good culture
Some uniques
Differentiated customer and product portfolio
Sustainability is important
Stable Large shareholder and/or long term investor
Medium risks for its business
Top 10 in its market
Small cyclical dependencies
Future proof or reliable business model
Well known brand
Cons
Little innovation
Growths slower than the competition